Thus, mAbs have a strong activity on tumors overexpressing their antigens, such as HER2, EGFR, VEGF, or CD20 which led to commercialized molecules that revolutionized the treatment of many solid tumors including lung, colorectal, or breast cancer (Table 2) [24,25]. The gene discussed is ERBB2; the disease is breast carcinoma.